<DOC>
	<DOCNO>NCT01705158</DOCNO>
	<brief_summary>The purpose study determine efficacy safety association carboplatine liposomal doxorubicin patient ovarian cancer relapse , sensitive platin .</brief_summary>
	<brief_title>Myocet ® - Carboplatine Ovarian Cancer Relapse , Sensitive Platinum</brief_title>
	<detailed_description>In front shortage Caelyx , implementation alternative treatment must consider treat patient ovarian cancer relapse , sensitive platin : associate carboplatin another drug family doxorubicin : liposomal doxorubicin ( Myocet® ) .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>First second relapse carcinoma ovary , fallopian tube peritoneal tissue histological prove . Interval without progress &gt; 6 month last administration salt platinum ( deck ) . Measurable Disease ( accord criterion RECIST 1.1 ) assessable disease accord CA125 ( accord criterion GCIG ) . Satisfactory biological Balance sheet ( Assessment ) , accord follow criterion : Neutrophiles &gt; 1,5x 109/L , Plaques &gt; 100 x 109/L , Haemoglobin &gt; 9,0 g/dL . Bilirubine &lt; 1.5 x LSN ( Normal Superior Limit ) , transaminases alkaline phosphatase &lt; 2 . 5 x LSN . Creatinin clearance &gt; 50 mL/min calculate accord formula CockroftGault MDRD . Performance status &lt; 2 . Life expectancy least 12 week . Age &gt; 18 year . Capacity follow protocol . Consent sign procedure inclusion . Membership national insurance scheme . Tumor mild histology borderline , malignant epithelial tumor ovary , fallopian tube peritoneal tissue ( eg . tumor germ cell , tumor sexual cord stroma ) . History abdominal pelvic radiotherapy . Patient receive 2 line chemotherapy . Patient 3rd relapse . History another malignant tumor last 5 year , exception carcinoma situ neck womb squamouscell carcinoma skin treat adequate way solid tumor consider forgiveness completes without relapse least 5 year . Patients stubborn illness platinum , ( eg . progress last chemotherapy 6 month follow last administration platinum ) . Occlusive subocclusive disease presence symptomatic intellectual metastasis . Heart disorder dissuade use anthracycline . Left venticular ejection fraction ( LVEF ) define MUGA/ECHO &lt; 50 % . Wait present severe infection . Woman old enough procreate use adequate contraceptive method . Concomitant disease allow surgery and/or chemotherapy . Pathology severe concomitant compatible take study treatment participation patient study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ovarian cancer relapse</keyword>
	<keyword>sensitive platin</keyword>
</DOC>